Volume 16 Issue 9, September 2019

The transfer of the longevity-associated variant of BPIFB4 to Apoe^–/– mice fed a high-fat diet via gene therapy halted plaque formation and reduced inflammation.

In a 15-year follow-up of the VADT study, no differences in major cardiovascular outcomes were found among individuals with type 2 diabetes mellitus who underwent either intensive or standard glucose control. These results indicate that intensification of glycaemic control might not be expected to mitigate the risk of cardiovascular events.

Mutations in genes that encode components of desmosomes are the predominant cause of arrhythmogenic cardiomyopathy, a genetic disorder characterized by fibrofatty replacement of myocardial tissue and the risk of life-threatening arrhythmias. In this Review, the authors discuss the molecular mechanisms underlying the pathogenesis of this condition.

Tricuspid valve disease, particularly tricuspid regurgitation, is a highly prevalent condition with complex pathophysiology and long-term adverse consequences. In this Review, Rodés-Cabau and colleagues discuss the latest insights on the natural history and clinical and imaging assessment of tricuspid valve disease, highlighting the surgical management and emerging transcatheter therapies that are transforming clinical practice for this challenging disease.

Conflicting findings about the effects of testosterone replacement therapy on the risk of cardiovascular disease have been reported in various studies and clinical trials. In this Review, Gagliano-Jucá and Basaria discuss the design, outcomes and shortcomings of studies on testosterone replacement therapy, as well as studies examining the cardiovascular effects of testosterone in vitro, in animals and in humans.